Literature DB >> 15488564

PET imaging in gynecologic malignancies.

Rakesh Kumar1, Abass Alavi.   

Abstract

FDG-PET has a definite role in detecting lymph node involvement and distant metastases. It has also shown encouraging results in assessing tumor recurrence and restaging, but further studies are required before FDG-PET can be incorporated in routine clinical practice for diagnosis of recurrence. In ovarian cancer, FDG-PET has high sensitivity and specificity in identifying patients with recurrent tumor, but lesion localization is difficult with PET. Normal FDG activity in the gastrointestinal tract and bladder may obscure some lesions. Combined PET/CT can help in localizing lesions and differentiating between pathologic and physiologic uptake in the pelvis and abdomen.

Entities:  

Mesh:

Year:  2004        PMID: 15488564     DOI: 10.1016/j.rcl.2004.08.006

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  9 in total

1.  The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy.

Authors:  D Wydra; S Sawicki; T Bandurski
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06       Impact factor: 9.236

2.  Cervical cancer: MR imaging findings before, during, and after radiation therapy.

Authors:  Gulgun Engin
Journal:  Eur Radiol       Date:  2005-06-14       Impact factor: 5.315

3.  Clinical Applications of PET and PET-CT.

Authors:  S S Anand; H Singh; A K Dash
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 4.  A new dimension of FDG-PET interpretation: assessment of tumor biology.

Authors:  Thomas C Kwee; Sandip Basu; Babak Saboury; Valentina Ambrosini; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

5.  An analysis of the utility of handheld PET probes for the intraoperative localization of malignant tissue.

Authors:  Segundo Jaime González; Lorena González; Joyce Wong; Peter Brader; Maureen Zakowski; Mithat Gönen; Farhad Daghighian; Yuman Fong; Vivian E Strong
Journal:  J Gastrointest Surg       Date:  2010-11-25       Impact factor: 3.452

6.  Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.

Authors:  Hyun Hoon Chung; Won Jun Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang; Hyo-Pyo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-07       Impact factor: 9.236

7.  Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.

Authors:  Till A Heusner; Sherko Kuemmel; Steffen Hahn; Angela Koeninger; Friedrich Otterbach; Monia E Hamami; Klaus R Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-05       Impact factor: 9.236

Review 8.  PET/CT and cross sectional imaging of gynecologic malignancy.

Authors:  Revathy B Iyer; Aparna Balachandran; Catherine E Devine
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

9.  The effectiveness of dual-phase 18F-FDG PET/CT in the detection of epithelial ovarian carcinoma: a pilot study.

Authors:  Jae Kwan Lee; Kyung-Jin Min; Kyeong A So; Sungeun Kim; Jin Hwa Hong
Journal:  J Ovarian Res       Date:  2014-02-05       Impact factor: 4.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.